Toro Company vice president Amy Dahl to depart at end of September
Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold a total of 49,792 ordinary shares of the company on September 9th and 10th. The sales were executed at prices ranging from $20 to $22, totaling $1,045,840.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024.
On the same dates, Bush also exercised options to acquire a total of 49,792 ordinary shares at prices of $8.01 and $9.42, amounting to $434,083.
In other recent news, Centessa Pharmaceuticals has been the focus of several analyst updates. Oppenheimer has resumed coverage of the company with an Outperform rating and set a price target of $40. This decision reflects the firm’s strong belief in Centessa’s lead asset, ORX750, which is considered to have best-in-class potential among orexin-2 receptor agonists. Truist Securities has also reiterated its Buy rating and maintained a $30 price target as the company approaches the release of Phase 2a data for ORX750, expected by year-end. This upcoming data is seen as a significant catalyst for Centessa. Additionally, Truist Securities recently initiated coverage of Centessa with a Buy rating, emphasizing the potential of ORX750 in treating narcolepsy and idiopathic hypersomnia. These developments highlight ongoing interest and optimism from analysts regarding Centessa’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.